

Haematologica
HAEMATOL/2019/242206
Version 3

Genetic heterogeneity highlighted by differential FDG-PET response in
diffuse large B-cell lymphoma

Shamzah Araf, Koorosh Korfi¹, Findlay Bewicke-Copley, Jun Wang,
Sergio Cogliatti, Emil Kumar, Flavio Forrer, Sally F. Barrington, Trevor
A. Graham, David W. Scott, Lisa M. Rimsza, Andrew Davies, Peter
Johnson, Jessica Okosun, Jude Fitzgibbon, and Martin Fehr

Disclosures: DWS and LMR are named inventors on a patent licensed to NanoString Technologies. PJ declares research funding from Janssen Pharmaceutical Companies and JF declares research funding from Epizyme. KK is a Hoffmann-La Roche consultant. This work was supported by grants from Cancer Research UK (15968 awarded to J.F, Clinical Research Fellowship awarded to S.A) and Bloodwise through funding of the Precision Medicine for Aggressive Lymphoma (PMAL) consortium (15002). SFB acknowledges support from the National Institute for Health Research and Social Care (NIHR) [RP-2-16-07-001]. King's College London and UCL Comprehensive Cancer Imaging Centre is funded by the CRUK and EPSRC in association with the MRC and Department of Health and Social Care (England). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Contributions: SA JO, JF and MF conceived the study. SA, JO and JF designed the study, SA, JO, JF, FB, SC and MF wrote the manuscript, MF, SC identified the patient for the study and collected clinical information, SC performed the pathological review of specimens, FB, JW performed the bioinformatic analysis, SA, KK, EK, performed experiments, SA, KK, FB, JW, EK, SC, MF, FF, SFB, DWS, LMR, AD, PJ, JO, JF, TAG analyzed the data. All authors read, critically reviewed and approved the manuscript.